Mind Medicine (MindMed) Inc.
MMCWF
Other OTC0.07
USD
+0.06
- -
Return %
Stock
S&P500
1Y
-60.18
26.84
3Y
-93.23
77.03
5Y
-93.23
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Similar Companies
- Business
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a late-stage clinical biopharmaceutical company that develops novel product candidates targeting neurotransmitter pathways to treat brain health disorders, including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). Founded in 2019 and headquartered in New York, New York, the company focuses on pharmaceutically optimized formulations derived from psychedelics and empathogens; its lead product candidate, MM120 Orally Disintegrating Tablet (ODT; lysergide D-tartrate or LSD), advances in multiple Phase 3 trials for GAD (Voyage and Panorama studies, with topline data expected in 1H 2026 and 2H 2026, respectively) and MDD (Emerge study, topline mid-2026, and planned Ascend study initiation mid-2026), following positive Phase 2b results published in the Journal of the American Medical Association demonstrating significant symptom reduction, 65% clinical response rate, and 48% remission rate at the optimal 100 µg dose, which earned FDA Breakthrough Therapy Designation in March 2024. MM402 (R(-)-MDMA), a proprietary enantiomer of 3,4-methylenedioxymethamphetamine designed for reduced neurotoxicity and abuse liability, completes Phase 1 and prepares for Phase 2a initiation in 4Q 2025 to address core socialization and communication symptoms in adult ASD patients. In recent developments, MindMed completed a $258.9 million public offering on October 31, 2025, yielding $242.8 million in net proceeds to fund operations into 2028 and support pipeline advancement; the company maintains cash, equivalents, and investments of $209.1 million as of September 30, 2025, while progressing enrollment in pivotal trials and exploring additional indications for MM120 ODT and MM402. MindMed operates primarily in the United States and Europe, serving patients with unmet needs in psychiatric and neurodevelopmental disorders through its clinical-stage pipeline.